HEADER OXIDOREDUCTASE 29-SEP-05 2C2S TITLE HUMAN DIHYDROFOLATE REDUCTASE COMPLEXED WITH NADPH AND 2,4-DIAMINO-5- TITLE 2 (1-O-CARBORANYLMETHYL)-6-METHYLPYRIMIDINE, A NOVEL BORON CONTAINING, TITLE 3 NONCLASSICAL ANTIFOLATE COMPND MOL_ID: 1; COMPND 2 MOLECULE: DIHYDROFOLATE REDUCTASE; COMPND 3 CHAIN: A, B; COMPND 4 EC: 1.5.1.3; COMPND 5 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 6 EXPRESSION_SYSTEM_TAXID: 469008; SOURCE 7 EXPRESSION_SYSTEM_STRAIN: BL21(DE3); SOURCE 8 EXPRESSION_SYSTEM_VECTOR: PET11A; SOURCE 9 EXPRESSION_SYSTEM_PLASMID: PDFR KEYWDS NONCLASSICAL ANTIFOLATES, LIPOPHILIC ANTIFOLATES, NADP, ONE- CARBON KEYWDS 2 METABOLISM, OXIDOREDUCTASE, REDUCTASE EXPDTA X-RAY DIFFRACTION AUTHOR A.K.W.LEUNG,R.C.REYNOLDS,J.M.RIORDAN,D.W.BORHANI REVDAT 6 08-MAY-19 2C2S 1 REMARK REVDAT 5 06-MAR-19 2C2S 1 REMARK REVDAT 4 24-FEB-09 2C2S 1 VERSN REVDAT 3 17-JUL-07 2C2S 1 JRNL REVDAT 2 26-JUN-07 2C2S 1 JRNL REVDAT 1 10-APR-07 2C2S 0 JRNL AUTH R.C.REYNOLDS,S.R.CAMPBELL,R.G.FAIRCHILD,R.L.KISLIUK, JRNL AUTH 2 P.L.MICCA,S.F.QUEENER,J.M.RIORDAN,W.D.SEDWICK,W.R.WAUD, JRNL AUTH 3 A.K.W.LEUNG,R.W.DIXON,W.J.SULING,D.W.BORHANI JRNL TITL NOVEL BORON-CONTAINING, NONCLASSICAL ANTIFOLATES: SYNTHESIS JRNL TITL 2 AND PRELIMINARY BIOLOGICAL AND STRUCTURAL EVALUATION. JRNL REF J.MED.CHEM. V. 50 3283 2007 JRNL REFN ISSN 0022-2623 JRNL PMID 17569517 JRNL DOI 10.1021/JM0701977 REMARK 2 REMARK 2 RESOLUTION. 1.40 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : REFMAC 5.2.0019 REMARK 3 AUTHORS : MURSHUDOV,SKUBAK,LEBEDEV,PANNU,STEINER, REMARK 3 : NICHOLLS,WINN,LONG,VAGIN REMARK 3 REMARK 3 REFINEMENT TARGET : MAXIMUM LIKELIHOOD REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.40 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 20.00 REMARK 3 DATA CUTOFF (SIGMA(F)) : NULL REMARK 3 COMPLETENESS FOR RANGE (%) : 83.9 REMARK 3 NUMBER OF REFLECTIONS : 61984 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.157 REMARK 3 R VALUE (WORKING SET) : 0.155 REMARK 3 FREE R VALUE : 0.198 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.000 REMARK 3 FREE R VALUE TEST SET COUNT : 3260 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 20 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 1.40 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 1.44 REMARK 3 REFLECTION IN BIN (WORKING SET) : 2295 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 42.60 REMARK 3 BIN R VALUE (WORKING SET) : 0.2130 REMARK 3 BIN FREE R VALUE SET COUNT : 122 REMARK 3 BIN FREE R VALUE : 0.3420 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 2962 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 146 REMARK 3 SOLVENT ATOMS : 556 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 16.10 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 19.68 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : -0.16000 REMARK 3 B22 (A**2) : 0.18000 REMARK 3 B33 (A**2) : -0.02000 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED OVERALL COORDINATE ERROR. REMARK 3 ESU BASED ON R VALUE (A): 0.086 REMARK 3 ESU BASED ON FREE R VALUE (A): 0.074 REMARK 3 ESU BASED ON MAXIMUM LIKELIHOOD (A): 0.048 REMARK 3 ESU FOR B VALUES BASED ON MAXIMUM LIKELIHOOD (A**2): 2.682 REMARK 3 REMARK 3 CORRELATION COEFFICIENTS. REMARK 3 CORRELATION COEFFICIENT FO-FC : 0.972 REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : 0.958 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES COUNT RMS WEIGHT REMARK 3 BOND LENGTHS REFINED ATOMS (A): 3344 ; 0.014 ; 0.022 REMARK 3 BOND LENGTHS OTHERS (A): 2324 ; 0.001 ; 0.020 REMARK 3 BOND ANGLES REFINED ATOMS (DEGREES): 4726 ; 1.553 ; 2.017 REMARK 3 BOND ANGLES OTHERS (DEGREES): 5769 ; 1.213 ; 2.979 REMARK 3 TORSION ANGLES, PERIOD 1 (DEGREES): 374 ; 6.022 ; 5.000 REMARK 3 TORSION ANGLES, PERIOD 2 (DEGREES): 144 ;39.123 ;25.278 REMARK 3 TORSION ANGLES, PERIOD 3 (DEGREES): 595 ;12.650 ;15.000 REMARK 3 TORSION ANGLES, PERIOD 4 (DEGREES): 13 ;12.302 ;15.000 REMARK 3 CHIRAL-CENTER RESTRAINTS (A**3): 493 ; 0.094 ; 0.200 REMARK 3 GENERAL PLANES REFINED ATOMS (A): 3465 ; 0.007 ; 0.020 REMARK 3 GENERAL PLANES OTHERS (A): 580 ; 0.001 ; 0.020 REMARK 3 NON-BONDED CONTACTS REFINED ATOMS (A): 512 ; 0.203 ; 0.200 REMARK 3 NON-BONDED CONTACTS OTHERS (A): 2256 ; 0.192 ; 0.200 REMARK 3 NON-BONDED TORSION REFINED ATOMS (A): 1486 ; 0.177 ; 0.200 REMARK 3 NON-BONDED TORSION OTHERS (A): 1688 ; 0.085 ; 0.200 REMARK 3 H-BOND (X...Y) REFINED ATOMS (A): 331 ; 0.132 ; 0.200 REMARK 3 H-BOND (X...Y) OTHERS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY VDW REFINED ATOMS (A): 10 ; 0.174 ; 0.200 REMARK 3 SYMMETRY VDW OTHERS (A): 64 ; 0.202 ; 0.200 REMARK 3 SYMMETRY H-BOND REFINED ATOMS (A): 47 ; 0.147 ; 0.200 REMARK 3 SYMMETRY H-BOND OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 MAIN-CHAIN BOND REFINED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 MAIN-CHAIN BOND OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE REFINED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN BOND REFINED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN BOND OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE REFINED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 LONG RANGE B REFINED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 LONG RANGE B OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 REMARK 3 ANISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 RIGID-BOND RESTRAINTS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; FREE ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; BONDED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 REMARK 3 NCS RESTRAINTS STATISTICS REMARK 3 NUMBER OF DIFFERENT NCS GROUPS : NULL REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : 2 REMARK 3 REMARK 3 TLS GROUP : 1 REMARK 3 NUMBER OF COMPONENTS GROUP : 1 REMARK 3 COMPONENTS C SSSEQI TO C SSSEQI REMARK 3 RESIDUE RANGE : A 1 A 300 REMARK 3 ORIGIN FOR THE GROUP (A): 0.5380 23.7040 -1.1690 REMARK 3 T TENSOR REMARK 3 T11: -0.1272 T22: -0.1407 REMARK 3 T33: -0.1257 T12: -0.0300 REMARK 3 T13: -0.0287 T23: 0.0106 REMARK 3 L TENSOR REMARK 3 L11: 2.0098 L22: 1.1534 REMARK 3 L33: 1.6281 L12: 0.3200 REMARK 3 L13: -0.1374 L23: 0.2478 REMARK 3 S TENSOR REMARK 3 S11: 0.0446 S12: -0.1704 S13: -0.0967 REMARK 3 S21: 0.1947 S22: -0.0426 S23: -0.1054 REMARK 3 S31: 0.1325 S32: 0.0099 S33: -0.0020 REMARK 3 REMARK 3 TLS GROUP : 2 REMARK 3 NUMBER OF COMPONENTS GROUP : 1 REMARK 3 COMPONENTS C SSSEQI TO C SSSEQI REMARK 3 RESIDUE RANGE : B 1 B 300 REMARK 3 ORIGIN FOR THE GROUP (A): 21.1790 45.1760 22.7100 REMARK 3 T TENSOR REMARK 3 T11: -0.1356 T22: -0.1278 REMARK 3 T33: -0.1332 T12: 0.0424 REMARK 3 T13: 0.0057 T23: 0.0005 REMARK 3 L TENSOR REMARK 3 L11: 1.1822 L22: 1.5571 REMARK 3 L33: 1.9551 L12: -0.3139 REMARK 3 L13: -0.2629 L23: 0.6835 REMARK 3 S TENSOR REMARK 3 S11: -0.0844 S12: -0.1846 S13: 0.0463 REMARK 3 S21: 0.1180 S22: 0.0334 S23: 0.0105 REMARK 3 S31: 0.0296 S32: 0.0064 S33: 0.0510 REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : BABINET MODEL WITH MASK REMARK 3 PARAMETERS FOR MASK CALCULATION REMARK 3 VDW PROBE RADIUS : 1.40 REMARK 3 ION PROBE RADIUS : 0.80 REMARK 3 SHRINKAGE RADIUS : 0.80 REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: HYDROGENS HAVE BEEN ADDED IN THE RIDING REMARK 3 POSITIONS. REMARK 4 REMARK 4 2C2S COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 29-SEP-05. REMARK 100 THE DEPOSITION ID IS D_1290025677. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 02-MAR-99 REMARK 200 TEMPERATURE (KELVIN) : 100.0 REMARK 200 PH : 8.00 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : SSRL REMARK 200 BEAMLINE : BL9-1 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.78300 REMARK 200 MONOCHROMATOR : SI (111) REMARK 200 OPTICS : MIRROR REMARK 200 REMARK 200 DETECTOR TYPE : IMAGE PLATE REMARK 200 DETECTOR MANUFACTURER : MARRESEARCH REMARK 200 INTENSITY-INTEGRATION SOFTWARE : MOSFLM REMARK 200 DATA SCALING SOFTWARE : SCALA REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 65300 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.400 REMARK 200 RESOLUTION RANGE LOW (A) : 35.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 0.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 84.0 REMARK 200 DATA REDUNDANCY : 3.000 REMARK 200 R MERGE (I) : 0.05000 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 11.2000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.40 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 1.44 REMARK 200 COMPLETENESS FOR SHELL (%) : 43.1 REMARK 200 DATA REDUNDANCY IN SHELL : 1.30 REMARK 200 R MERGE FOR SHELL (I) : 0.46000 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 1.500 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: AMORE REMARK 200 STARTING MODEL: UNPUBLISHED HUMAN DHFR STRUCTURE REMARK 200 REMARK 200 REMARK: INTENSITIES WERE CONVERTED TO STRUCTURE FACTORS USING CCP4 REMARK 200 PROGRAM TRUNCATE. REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 46.30 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.30 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: THE TERNARY COMPLEX OF DHFR WITH NADPH REMARK 280 AND 34B WAS FORMED BY MIXING HUMAN DHFR (20 MG/ML IN 25 MM KPO4 REMARK 280 (PH 7.0), 0.1 MM EDTA, AND 3 MM NAN3) WITH 60 MM NADPH, FOLLOWED REMARK 280 15 MINUTES LATER BY 60 MM OF INHIBITOR IN DMSO (FINAL REMARK 280 CONCENTRATIONS OF 2 MM NADPH AND 2 MM INHIBITOR). THIS COMPLEX REMARK 280 SOLUTION WAS MIXED WITH AN EQUAL VOLUME OF PRECIPITANT REMARK 280 CONTAINING 24-33% PEG 4000, 0.2 M LI2SO4, 0.1 M TRIS CL (PH 7.9- REMARK 280 8.4), 5% GLYCEROL, AND EQUILIBRATED WITH THE PRECIPITANT BY REMARK 280 HANGING DROP VAPOR DIFFUSION AT 277 K. THE CRYSTAL GREW IN ABOUT REMARK 280 3 WEEKS. THE CRYSTAL WAS FLASH-COOLED DIRECTLY IN LIQUID REMARK 280 NITROGEN AFTER HARVESTING INTO MOTHER LIQUOR CONTAINING 10% REMARK 280 GLYCEROL., PH 8.00, VAPOR DIFFUSION, HANGING DROP REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: C 2 2 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,-Y,Z+1/2 REMARK 290 3555 -X,Y,-Z+1/2 REMARK 290 4555 X,-Y,-Z REMARK 290 5555 X+1/2,Y+1/2,Z REMARK 290 6555 -X+1/2,-Y+1/2,Z+1/2 REMARK 290 7555 -X+1/2,Y+1/2,-Z+1/2 REMARK 290 8555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 47.89100 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 47.89100 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 5 1.000000 0.000000 0.000000 43.83550 REMARK 290 SMTRY2 5 0.000000 1.000000 0.000000 46.93200 REMARK 290 SMTRY3 5 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 6 -1.000000 0.000000 0.000000 43.83550 REMARK 290 SMTRY2 6 0.000000 -1.000000 0.000000 46.93200 REMARK 290 SMTRY3 6 0.000000 0.000000 1.000000 47.89100 REMARK 290 SMTRY1 7 -1.000000 0.000000 0.000000 43.83550 REMARK 290 SMTRY2 7 0.000000 1.000000 0.000000 46.93200 REMARK 290 SMTRY3 7 0.000000 0.000000 -1.000000 47.89100 REMARK 290 SMTRY1 8 1.000000 0.000000 0.000000 43.83550 REMARK 290 SMTRY2 8 0.000000 -1.000000 0.000000 46.93200 REMARK 290 SMTRY3 8 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1, 2 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PQS REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 2 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PQS REMARK 350 APPLY THE FOLLOWING TO CHAINS: B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 375 REMARK 375 SPECIAL POSITION REMARK 375 THE FOLLOWING ATOMS ARE FOUND TO BE WITHIN 0.15 ANGSTROMS REMARK 375 OF A SYMMETRY RELATED ATOM AND ARE ASSUMED TO BE ON SPECIAL REMARK 375 POSITIONS. REMARK 375 REMARK 375 ATOM RES CSSEQI REMARK 375 HOH B2280 LIES ON A SPECIAL POSITION. REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 ARG A 28 NE CZ NH1 NH2 REMARK 470 LYS A 80 CG CD CE NZ REMARK 470 ARG A 91 NE CZ NH1 NH2 REMARK 470 LYS A 108 CD CE NZ REMARK 470 ARG B 28 NE CZ NH1 NH2 REMARK 470 GLU B 44 CG CD OE1 OE2 REMARK 470 LYS B 63 CG CD CE NZ REMARK 470 GLU B 78 CD OE1 OE2 REMARK 470 ARG B 91 CD NE CZ NH1 NH2 REMARK 470 GLU B 150 CG CD OE1 OE2 REMARK 470 GLU B 161 CD OE1 OE2 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ASP A 110 -97.58 -95.22 REMARK 500 MET A 139 49.68 -87.24 REMARK 500 ASP B 110 -96.71 -100.96 REMARK 500 MET B 139 41.90 -88.88 REMARK 500 REMARK 500 REMARK: NULL REMARK 525 REMARK 525 SOLVENT REMARK 525 REMARK 525 THE SOLVENT MOLECULES HAVE CHAIN IDENTIFIERS THAT REMARK 525 INDICATE THE POLYMER CHAIN WITH WHICH THEY ARE MOST REMARK 525 CLOSELY ASSOCIATED. THE REMARK LISTS ALL THE SOLVENT REMARK 525 MOLECULES WHICH ARE MORE THAN 5A AWAY FROM THE REMARK 525 NEAREST POLYMER CHAIN (M = MODEL NUMBER; REMARK 525 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE REMARK 525 NUMBER; I=INSERTION CODE): REMARK 525 REMARK 525 M RES CSSEQI REMARK 525 HOH A2012 DISTANCE = 6.48 ANGSTROMS REMARK 525 HOH A2020 DISTANCE = 6.01 ANGSTROMS REMARK 525 HOH A2037 DISTANCE = 6.68 ANGSTROMS REMARK 525 HOH A2038 DISTANCE = 6.31 ANGSTROMS REMARK 525 HOH A2100 DISTANCE = 5.86 ANGSTROMS REMARK 525 HOH B2030 DISTANCE = 5.81 ANGSTROMS REMARK 525 HOH B2041 DISTANCE = 6.36 ANGSTROMS REMARK 700 REMARK 700 SHEET REMARK 700 THE SHEET STRUCTURE OF THIS MOLECULE IS BIFURCATED. IN REMARK 700 ORDER TO REPRESENT THIS FEATURE IN THE SHEET RECORDS BELOW, REMARK 700 TWO SHEETS ARE DEFINED. REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE NDP A1187 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE 34B A1188 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE NDP B1187 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC4 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE 34B B1188 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC5 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE GOL B1189 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1BOZ RELATED DB: PDB REMARK 900 STRUCTURE-BASED DESIGN AND SYNTHESIS OF LIPOPHILIC 2,4- DIAMINO-6- REMARK 900 SUBSTITUTED QUINAZOLINES AND THEIR EVALUATION AS INHIBITORS OF REMARK 900 DIHYDROFOLATE REDUCTASE AND POTENTIAL ANTITUMOR AGENTS REMARK 900 RELATED ID: 1DHF RELATED DB: PDB REMARK 900 DIHYDROFOLATE REDUCTASE (DHFR) COMPLEX WITH FOLATE REMARK 900 RELATED ID: 1DLR RELATED DB: PDB REMARK 900 DIHYDROFOLATE REDUCTASE (DHFR) MUTANT WITH LEU 22 REPLACED BY PHE REMARK 900 (L22F) COMPLEXED WITH NADPH AND PIRITREXIM (PTX) REMARK 900 RELATED ID: 1DLS RELATED DB: PDB REMARK 900 DIHYDROFOLATE REDUCTASE (DHFR) MUTANT WITH LEU 22 REPLACED BY TYR REMARK 900 (L22Y) COMPLEXED WITH NADPH AND METHOTREXATE REMARK 900 RELATED ID: 1DRF RELATED DB: PDB REMARK 900 DIHYDROFOLATE REDUCTASE COMPLEX WITH FOLATE REMARK 900 RELATED ID: 1HFP RELATED DB: PDB REMARK 900 COMPARISON OF TERNARY CRYSTAL COMPLEXES OF HUMAN DIHYDROFOLATE REMARK 900 REDUCTASE WITH NADPH AND A CLASSICAL ANTITUMOR FUROPYRIMDINE REMARK 900 RELATED ID: 1HFQ RELATED DB: PDB REMARK 900 COMPARISON OF TERNARY CRYSTAL COMPLEXES OF HUMAN DIHYDROFOLATE REMARK 900 REDUCTASE WITH NADPH AND A CLASSICAL ANTITUMOR FUROPYRIMDINE REMARK 900 RELATED ID: 1HFR RELATED DB: PDB REMARK 900 COMPARISON OF TERNARY CRYSTAL COMPLEXES OF HUMAN DIHYDROFOLATE REMARK 900 REDUCTASE WITH NADPH AND A CLASSICAL ANTITUMOR FUROPYRIMDINE REMARK 900 RELATED ID: 1KMS RELATED DB: PDB REMARK 900 HUMAN DIHYDROFOLATE REDUCTASE COMPLEXED WITH NADPH AND 6-([5- REMARK 900 QUINOLYLAMINO]METHYL)-2,4 -DIAMINO-5-METHYLPYRIDO[2,3-D]PYRIMIDINE REMARK 900 ( SRI-9439), A LIPOPHILIC ANTIFOLATE REMARK 900 RELATED ID: 1KMV RELATED DB: PDB REMARK 900 HUMAN DIHYDROFOLATE REDUCTASE COMPLEXED WITH NADPH AND (Z)-6-(2-[2, REMARK 900 5-DIMETHOXYPHENYL] ETHEN-1-YL)-2,4-DIAMINO-5-METHYLPYRIDO[2 ,3-D] REMARK 900 PYRIMIDINE (SRI-9662), A LIPOPHILICANTIFOLATE REMARK 900 RELATED ID: 1MVS RELATED DB: PDB REMARK 900 ANALYSIS OF TWO POLYMORPHIC FORMS OF A PYRIDO[2,3-D]PYRIMIDINE N9- REMARK 900 C10 REVERSE- BRIDGE ANTIFOLATE BINARYCOMPLEX WITH HUMAN REMARK 900 DIHYDROFOLATE REDUCTASE REMARK 900 RELATED ID: 1MVT RELATED DB: PDB REMARK 900 ANALYSIS OF TWO POLYMORPHIC FORMS OF A PYRIDO[2,3-D]PYRIMIDINE N9- REMARK 900 C10 REVERSE- BRIDGE ANTIFOLATE BINARYCOMPLEX WITH HUMAN REMARK 900 DIHYDROFOLATE REDUCTASE REMARK 900 RELATED ID: 1OHJ RELATED DB: PDB REMARK 900 HUMAN DIHYDROFOLATE REDUCTASE, MONOCLINIC (P21 ) CRYSTAL FORM REMARK 900 RELATED ID: 1OHK RELATED DB: PDB REMARK 900 HUMAN DIHYDROFOLATE REDUCTASE, ORTHORHOMBIC (P21 21 21) CRYSTAL FORM REMARK 900 RELATED ID: 1PD8 RELATED DB: PDB REMARK 900 ANALYSIS OF THREE CRYSTAL STRUCTURE DETERMINATIONS OF A 5-METHYL-6- REMARK 900 N- METHYLANILINO PYRIDOPYRIMIDINE ANTIFOLATECOMPLEX WITH HUMAN REMARK 900 DIHYDROFOLATE REDUCTASE REMARK 900 RELATED ID: 1PD9 RELATED DB: PDB REMARK 900 ANALYSIS OF THREE CRYSTAL STRUCTURE DETERMINATIONS OF A 5-METHYL-6- REMARK 900 N- METHYLANILINO PYRIDOPYRIMIDINE ANTIFOLATECOMPLEX WITH HUMAN REMARK 900 DIHYDROFOLATE REDUCTASE REMARK 900 RELATED ID: 1PDB RELATED DB: PDB REMARK 900 ANALYSIS OF THREE CRYSTAL STRUCTURE DETERMINATIONS OF A 5-METHYL-6- REMARK 900 N- METHYLANILINO PYRIDOPYRIMIDINE ANTIFOLATECOMPLEX WITH HUMAN REMARK 900 DIHYDROFOLATE REDUCTASE REMARK 900 RELATED ID: 1S3U RELATED DB: PDB REMARK 900 STRUCTURE DETERMINATION OF TETRAHYDROQUINAZOLINEANTIFOLATES IN REMARK 900 COMPLEX WITH HUMAN AND PNEUMOCYSTIS CARINIIDIHYDROFOLATE REDUCTASE: REMARK 900 CORRELATIONS OF ENZYMESELECTIVITY AND STEREOCHEMISTRY REMARK 900 RELATED ID: 1S3V RELATED DB: PDB REMARK 900 STRUCTURE DETERMINATION OF TETRAHYDROQUINAZOLINEANTIFOLATES IN REMARK 900 COMPLEX WITH HUMAN AND PNEUMOCYSTIS CARINIIDIHYDROFOLATE REDUCTASE: REMARK 900 CORRELATIONS OF ENZYMESELECTIVITY AND STEREOCHEMISTRY REMARK 900 RELATED ID: 1S3W RELATED DB: PDB REMARK 900 STRUCTURE DETERMINATION OF TETRAHYDROQUINAZOLINEANTIFOALTES IN REMARK 900 COMPLEX WITH HUMAN AND PNEUMOCYSTIS CARINIIDIHYDROFOLATE REDUCTASE: REMARK 900 CORRELATIONS OF ENZYMESELECTIVITY AND STEREOCHEMISTRY REMARK 900 RELATED ID: 1U71 RELATED DB: PDB REMARK 900 UNDERSTANDING THE ROLE OF LEU22 VARIANTS IN METHOTREXATERESISTANCE: REMARK 900 COMPARISON OF WILD- TYPE AND LEU22ARG VARIANTMOUSE AND HUMAN REMARK 900 DIHYDROFOLATE REDUCTASE TERNARY CRYSTALCOMPLEXES WITH METHOTREXATE REMARK 900 AND NADPH REMARK 900 RELATED ID: 1U72 RELATED DB: PDB REMARK 900 UNDERSTANDING THE ROLE OF LEU22 VARIANTS IN METHOTREXATERESISTANCE: REMARK 900 COMPARISON OF WILD- TYPE AND LEU22ARG VARIANTMOUSE AND HUMAN REMARK 900 DIHYDRFOLATE REDUCTASE TERNARY CRYSTALCOMPLEXES WITH METHOTREXATE REMARK 900 AND NADPH REMARK 900 RELATED ID: 2C2T RELATED DB: PDB REMARK 900 HUMAN DIHYDROFOLATE REDUCTASE COMPLEXED WITH NADPH AND 2,4-DIAMINO- REMARK 900 5-((7,8- DICARBAUNDECABORAN-7-YL)METHYL)-6- METHYLPYRIMIDINE, A REMARK 900 NOVEL BORON CONTANING, NONCLASSICAL ANTIFOLATE REMARK 900 RELATED ID: 2DHF RELATED DB: PDB REMARK 900 DIHYDROFOLATE REDUCTASE (DHFR) COMPLEX WITH 5 -DEAZAFOLATE DBREF 2C2S A 1 186 UNP P00374 DYR_HUMAN 1 186 DBREF 2C2S B 1 186 UNP P00374 DYR_HUMAN 1 186 SEQRES 1 A 186 VAL GLY SER LEU ASN CYS ILE VAL ALA VAL SER GLN ASN SEQRES 2 A 186 MET GLY ILE GLY LYS ASN GLY ASP LEU PRO TRP PRO PRO SEQRES 3 A 186 LEU ARG ASN GLU PHE ARG TYR PHE GLN ARG MET THR THR SEQRES 4 A 186 THR SER SER VAL GLU GLY LYS GLN ASN LEU VAL ILE MET SEQRES 5 A 186 GLY LYS LYS THR TRP PHE SER ILE PRO GLU LYS ASN ARG SEQRES 6 A 186 PRO LEU LYS GLY ARG ILE ASN LEU VAL LEU SER ARG GLU SEQRES 7 A 186 LEU LYS GLU PRO PRO GLN GLY ALA HIS PHE LEU SER ARG SEQRES 8 A 186 SER LEU ASP ASP ALA LEU LYS LEU THR GLU GLN PRO GLU SEQRES 9 A 186 LEU ALA ASN LYS VAL ASP MET VAL TRP ILE VAL GLY GLY SEQRES 10 A 186 SER SER VAL TYR LYS GLU ALA MET ASN HIS PRO GLY HIS SEQRES 11 A 186 LEU LYS LEU PHE VAL THR ARG ILE MET GLN ASP PHE GLU SEQRES 12 A 186 SER ASP THR PHE PHE PRO GLU ILE ASP LEU GLU LYS TYR SEQRES 13 A 186 LYS LEU LEU PRO GLU TYR PRO GLY VAL LEU SER ASP VAL SEQRES 14 A 186 GLN GLU GLU LYS GLY ILE LYS TYR LYS PHE GLU VAL TYR SEQRES 15 A 186 GLU LYS ASN ASP SEQRES 1 B 186 VAL GLY SER LEU ASN CYS ILE VAL ALA VAL SER GLN ASN SEQRES 2 B 186 MET GLY ILE GLY LYS ASN GLY ASP LEU PRO TRP PRO PRO SEQRES 3 B 186 LEU ARG ASN GLU PHE ARG TYR PHE GLN ARG MET THR THR SEQRES 4 B 186 THR SER SER VAL GLU GLY LYS GLN ASN LEU VAL ILE MET SEQRES 5 B 186 GLY LYS LYS THR TRP PHE SER ILE PRO GLU LYS ASN ARG SEQRES 6 B 186 PRO LEU LYS GLY ARG ILE ASN LEU VAL LEU SER ARG GLU SEQRES 7 B 186 LEU LYS GLU PRO PRO GLN GLY ALA HIS PHE LEU SER ARG SEQRES 8 B 186 SER LEU ASP ASP ALA LEU LYS LEU THR GLU GLN PRO GLU SEQRES 9 B 186 LEU ALA ASN LYS VAL ASP MET VAL TRP ILE VAL GLY GLY SEQRES 10 B 186 SER SER VAL TYR LYS GLU ALA MET ASN HIS PRO GLY HIS SEQRES 11 B 186 LEU LYS LEU PHE VAL THR ARG ILE MET GLN ASP PHE GLU SEQRES 12 B 186 SER ASP THR PHE PHE PRO GLU ILE ASP LEU GLU LYS TYR SEQRES 13 B 186 LYS LEU LEU PRO GLU TYR PRO GLY VAL LEU SER ASP VAL SEQRES 14 B 186 GLN GLU GLU LYS GLY ILE LYS TYR LYS PHE GLU VAL TYR SEQRES 15 B 186 GLU LYS ASN ASP HET NDP A1187 48 HET 34B A1188 22 HET NDP B1187 48 HET 34B B1188 22 HET GOL B1189 6 HETNAM NDP NADPH DIHYDRO-NICOTINAMIDE-ADENINE-DINUCLEOTIDE HETNAM 2 NDP PHOSPHATE HETNAM 34B 2,4-DIAMINO-5-(1-O-CARBORANYLMETHYL)-6-METHYLPYRIMIDINE HETNAM GOL GLYCEROL HETSYN GOL GLYCERIN; PROPANE-1,2,3-TRIOL FORMUL 3 NDP 2(C21 H30 N7 O17 P3) FORMUL 4 34B 2(C8 H20 B10 N4) FORMUL 7 GOL C3 H8 O3 FORMUL 8 HOH *556(H2 O) HELIX 1 1 LEU A 27 THR A 40 1 14 HELIX 2 2 LYS A 54 ILE A 60 1 7 HELIX 3 3 PRO A 61 ARG A 65 5 5 HELIX 4 4 SER A 92 THR A 100 1 9 HELIX 5 5 GLY A 117 HIS A 127 1 11 HELIX 6 6 LEU B 27 THR B 40 1 14 HELIX 7 7 LYS B 54 ILE B 60 1 7 HELIX 8 8 PRO B 61 ARG B 65 5 5 HELIX 9 9 SER B 92 THR B 100 1 9 HELIX 10 10 GLY B 117 ASN B 126 1 10 SHEET 1 AA 8 PHE A 88 SER A 90 0 SHEET 2 AA 8 ILE A 71 LEU A 75 1 O VAL A 74 N SER A 90 SHEET 3 AA 8 GLN A 47 GLY A 53 1 O ASN A 48 N ILE A 71 SHEET 4 AA 8 VAL A 109 ILE A 114 1 N ASP A 110 O GLN A 47 SHEET 5 AA 8 SER A 3 SER A 11 1 O ASN A 5 N ILE A 114 SHEET 6 AA 8 HIS A 130 ILE A 138 1 O HIS A 130 N LEU A 4 SHEET 7 AA 8 ILE A 175 LYS A 184 -1 O LYS A 178 N ARG A 137 SHEET 8 AA 8 LYS A 157 LEU A 158 -1 O LYS A 157 N GLU A 183 SHEET 1 AB 8 PHE A 88 SER A 90 0 SHEET 2 AB 8 ILE A 71 LEU A 75 1 O VAL A 74 N SER A 90 SHEET 3 AB 8 GLN A 47 GLY A 53 1 O ASN A 48 N ILE A 71 SHEET 4 AB 8 VAL A 109 ILE A 114 1 N ASP A 110 O GLN A 47 SHEET 5 AB 8 SER A 3 SER A 11 1 O ASN A 5 N ILE A 114 SHEET 6 AB 8 HIS A 130 ILE A 138 1 O HIS A 130 N LEU A 4 SHEET 7 AB 8 ILE A 175 LYS A 184 -1 O LYS A 178 N ARG A 137 SHEET 8 AB 8 GLN A 170 GLU A 172 -1 O GLN A 170 N TYR A 177 SHEET 1 AC 2 GLY A 15 GLY A 17 0 SHEET 2 AC 2 THR A 146 PHE A 147 -1 O THR A 146 N ILE A 16 SHEET 1 BA 8 PHE B 88 SER B 90 0 SHEET 2 BA 8 ARG B 70 LEU B 75 1 O VAL B 74 N SER B 90 SHEET 3 BA 8 GLN B 47 GLY B 53 1 O ASN B 48 N ILE B 71 SHEET 4 BA 8 VAL B 109 ILE B 114 1 N ASP B 110 O GLN B 47 SHEET 5 BA 8 SER B 3 VAL B 10 1 O ASN B 5 N ILE B 114 SHEET 6 BA 8 HIS B 130 ILE B 138 1 O HIS B 130 N LEU B 4 SHEET 7 BA 8 ILE B 175 LYS B 184 -1 O LYS B 178 N ARG B 137 SHEET 8 BA 8 LYS B 157 LEU B 158 -1 O LYS B 157 N GLU B 183 SHEET 1 BB 8 PHE B 88 SER B 90 0 SHEET 2 BB 8 ARG B 70 LEU B 75 1 O VAL B 74 N SER B 90 SHEET 3 BB 8 GLN B 47 GLY B 53 1 O ASN B 48 N ILE B 71 SHEET 4 BB 8 VAL B 109 ILE B 114 1 N ASP B 110 O GLN B 47 SHEET 5 BB 8 SER B 3 VAL B 10 1 O ASN B 5 N ILE B 114 SHEET 6 BB 8 HIS B 130 ILE B 138 1 O HIS B 130 N LEU B 4 SHEET 7 BB 8 ILE B 175 LYS B 184 -1 O LYS B 178 N ARG B 137 SHEET 8 BB 8 GLN B 170 GLU B 172 -1 O GLN B 170 N TYR B 177 SHEET 1 BC 2 GLY B 15 GLY B 17 0 SHEET 2 BC 2 THR B 146 PHE B 147 -1 O THR B 146 N ILE B 16 CISPEP 1 ARG A 65 PRO A 66 0 -7.17 CISPEP 2 GLY A 116 GLY A 117 0 0.63 CISPEP 3 ARG B 65 PRO B 66 0 -6.89 CISPEP 4 GLY B 116 GLY B 117 0 3.06 SITE 1 AC1 31 VAL A 8 ALA A 9 ILE A 16 GLY A 17 SITE 2 AC1 31 GLY A 20 ASP A 21 LEU A 22 GLY A 53 SITE 3 AC1 31 LYS A 54 LYS A 55 THR A 56 LEU A 75 SITE 4 AC1 31 SER A 76 ARG A 77 GLU A 78 ARG A 91 SITE 5 AC1 31 VAL A 115 GLY A 116 GLY A 117 SER A 118 SITE 6 AC1 31 SER A 119 VAL A 120 TYR A 121 GLU A 123 SITE 7 AC1 31 THR A 146 34B A1188 HOH A2179 HOH A2199 SITE 8 AC1 31 HOH A2266 HOH A2267 HOH A2268 SITE 1 AC2 9 ILE A 7 VAL A 8 ALA A 9 LEU A 22 SITE 2 AC2 9 GLU A 30 PHE A 34 VAL A 115 TYR A 121 SITE 3 AC2 9 NDP A1187 SITE 1 AC3 31 VAL B 8 ALA B 9 ILE B 16 GLY B 17 SITE 2 AC3 31 GLY B 20 ASP B 21 GLY B 53 LYS B 54 SITE 3 AC3 31 LYS B 55 THR B 56 LEU B 75 SER B 76 SITE 4 AC3 31 ARG B 77 GLU B 78 ARG B 91 VAL B 115 SITE 5 AC3 31 GLY B 117 SER B 118 SER B 119 VAL B 120 SITE 6 AC3 31 TYR B 121 GLU B 123 THR B 146 34B B1188 SITE 7 AC3 31 HOH B2195 HOH B2219 HOH B2220 HOH B2283 SITE 8 AC3 31 HOH B2284 HOH B2285 HOH B2286 SITE 1 AC4 8 ILE B 7 VAL B 8 ALA B 9 GLU B 30 SITE 2 AC4 8 PHE B 34 VAL B 115 TYR B 121 NDP B1187 SITE 1 AC5 7 LEU B 166 ASP B 168 VAL B 169 HOH B2251 SITE 2 AC5 7 HOH B2258 HOH B2287 HOH B2288 CRYST1 87.671 93.864 95.782 90.00 90.00 90.00 C 2 2 21 16 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.011406 0.000000 0.000000 0.00000 SCALE2 0.000000 0.010654 0.000000 0.00000 SCALE3 0.000000 0.000000 0.010440 0.00000 MTRIX1 1 -0.064193 0.996943 -0.044550 -2.42570 1 MTRIX2 1 -0.995562 -0.067055 -0.066028 47.20213 1 MTRIX3 1 -0.068813 0.040114 0.996823 22.86397 1